Celéri Health and a National Biologics Company Announce Real-World Evidence Partnership to Advance Outcomes Data for Regenerative Pain Therapies
Conshohocken, PA — Celéri Health and a national biologics company have entered into a real-world evidence partnership to generate structured, longitudinal outcomes data for the partner's regenerative tissue and biologic therapies used in interventional pain and spine care. Under the agreement, Celéri Health deploys its EaaS™ (Evidence-as-a-Service) platform to collect condition-specific patient-reported outcomes directly from patients, establishing a Commercial Insights Registry™ for the partner's portfolio. The engagement is structured to scale toward a Regulatory-Grade Evidence Cohort™ as the dataset matures — and expands Celéri Health's real-world data capabilities beyond neuromodulation into regenerative medicine.